Home

MARK J LEVIN

CIK 1180428 · last filed 2021-11-16

MARK J LEVIN is a corporate insider who has filed 89 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing shows the insider sold $95.5M of JNCE on Nov 16, 2021. Across all open-market trades the lifetime net is −$1.19B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $158.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$158.45M

Companies

14

Total Filings

89

Lifetime Open-Market Net

-$1.19B

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Jounce Therapeutics, Inc. (JNCE) Delisted 10%+ Owner 1,432,630 $1.88 $2.69M -$197.76M 2 2021-11-16
FULC Director 84,223 $3.87 $325.9K $1.30M 5 2021-11-12
RVMD 10%+ Owner 116,334 $216.00 $25.13M -$349.03M 3 2021-06-07
VYGR Director 6,424,205 $3.30 $21.20M $0 11 2021-06-04
NRIX 10%+ Owner 3,500,667 $26.93 $94.27M $0 1 2021-05-10
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted 10%+ Owner 3,034,083 $33.99 $103.13M $0 1 2018-08-24
MyoKardia, Inc. (MYOK) Delisted 10%+ Owner 280,057 — — $0 2 2018-03-07
Global Blood Therapeutics, Inc. (GBT) Delisted 10%+ Owner 4,475,191 $68.49 $306.51M -$470.21M 4 2017-04-06
CTMX 10%+ Owner 5,170,348 $3.39 $17.53M -$172.20M 2 2017-03-27
Blueprint Medicines Corp (BPMC) Delisted 10%+ Owner 3,570,197 $129.46 $462.20M -$1.23M 1 2017-03-20
Sage Therapeutics, Inc. (SAGE) Delisted 10%+ Owner 0 $8.68 $0 $0 1 2015-01-28
Carisma Therapeutics Inc. (EBIO) Delisted Director — — — $0 1 2014-03-24
Foundation Medicine, Inc. (FMI) Delisted Director 6,569,645 — — $0 1 2013-10-02
MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted Director 400,000 — — -$4.69M 54 2008-05-15

Recent Filings

89 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-11-16 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −11,400,000 -$95.53M EDGAR
2021-11-12 FULC Other (J) −1,000,000 $0 EDGAR
2021-09-24 FULC Other (J) −1,000,000 $0 EDGAR
2021-06-11 FULC Grant (A) — $0 EDGAR
2021-06-07 RVMD Sell (S) −3,258,678 -$98.44M EDGAR
2021-06-04 VYGR Grant (A) — $0 EDGAR
2021-05-27 RVMD Sell (S) −8,197,224 -$250.59M EDGAR
2021-05-10 NRIX Other (J) −6,514,704 $0 EDGAR
2021-03-03 Jounce Therapeutics, Inc. (JNCE) Delisted Sell (S) −8,700,000 -$102.22M EDGAR
2021-02-26 RVMD Other (J) −9,000,000 $0 EDGAR
Showing 1–10 of 89
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.